1 H.W. Rogers, M.A. Weinstock, S.R. Feldman, B.M. ColdironIncidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. Population, 2012 JAMA Dermatol, 151 (10) (2015), pp. 1081-1086, 10.1001/jamadermatol.2015.1187

2 A.L.S. Chang, J.A. Solomon, J.D. Hainsworth, et al.Expanded access study of patients with advanced basal ​cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib J Am Acad Dermatol, 70 (1) (2014), 10.1016/j.jaad.2013.09.012 60-9

3 M. Axelson, K. Liu, X. Jiang, et al.U.S. Food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma Clin Cancer Res, 19 (9) (2013), pp. 2289-2293, 10.1158/1078-0432.Ccr-12-1956

4 M. Pahlitzsch, E. Bertelmann, C. MaiConjunctival melanoma and BRAF inhibitor therapy J Clin Exp Ophthalmol, 5 (1) (2014), p. 322

5 X. Ju, P. Gaca, W. Fan, et al.Therapy failure and resistance mechanism in eyelid and ocular surface tumors Neurosignals, 30 (S1) (2022), pp. 21-38, 10.33594/000000560

6 A.C. Rokohl, K.R. Koch, J.M. Mor, et al.Personalized medicine in the treatment of periocular tumors : targeted treatment and use of immune checkpoint inhibitors Ophthalmologe, 117 (6) (2020), pp. 521-527, 10.1007/s00347-019-01034-z

7 C. Dessinioti, C. Antoniou, A. Katsambas, et al.Basal cell carcinoma: what’s new under the sun Photochem Photobiol, 86 (3) (2010), pp. 481-491, 10.1111/j.1751-1097.2010.00735.x

8 P. Subramaniam, C.M. Olsen, B.S. Thompson, et al.Anatomical distributions of basal cell carcinoma and squamous cell carcinoma in a population-based study in queensland, Australia JAMA Dermatology, 153 (2) (2017), pp. 175-182, 10.1001/jamadermatol.2016.4070

9 G. Winder, M. Kawar, A. ShalomAnatomical distribution of basal cell carcinoma in Israel using relative tumor density scores Int J Dermatol, 60 (11) (2021), pp. 1373-1375, 10.1111/ijd.15577

10 A.C. Krakowski, F. Hafeez, A. Westheim, et al.Advanced basal cell carcinoma: what dermatologists need to know about diagnosis J Am Acad Dermatol, 86 (6s) (2022), pp. S1-s13, 10.1016/j.jaad.2022.03.023

11 C. Dessinioti, A.J. StratigosAn epidemiological update on indoor tanning and the risk of skin cancers Curr Oncol, 29 (11) (2022), pp. 8886-8903, 10.3390/curroncol29110699

12 A.M. Molinaro, L.M. Ferrucci, B. Cartmel, et al.Indoor tanning and the MC1R genotype: risk prediction for basal cell carcinoma risk in young people Am J Epidemiol, 181 (11) (2015), pp. 908-916, 10.1093/aje/kwu356

13 A.C. Laga, I.M. Schaefer, L.M. Sholl, et al.Metastatic basal cell carcinoma: molecular ancillary testing and reappraisal of histopathology within a rare entity Am J Clin Pathol, 152 (6) (2019), pp. 706-717, 10.1093/ajcp/aqz089

14 C. Dessinioti, V. Sypsa, K. Kypreou, et al.A case-control study of MC1R variants in Greek patients with basal cell carcinoma: increased risk independently of pigmentary characteristics Exp Dermatol, 24 (6) (2015), pp. 476-478, 10.1111/exd.12703

15 E. Tagliabue, M.C. Fargnoli, S. Gandini, et al.MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project Br J Cancer, 113 (2) (2015), pp. 354-363, 10.1038/bjc.2015.231

16 C. Dessinioti, C. Antoniou, A.J. StratigosFrom basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots Br J Dermatol, 177 (6) (2017), pp. 1485-1494, 10.1111/bjd.15738

17 E.H. EpsteinBasal cell carcinomas: attack of the hedgehog Nat Rev Cancer, 8 (10) (2008), pp. 743-754, 10.1038/nrc2503

18 E. Montagna, O.S. LopesMolecular basis of basal cell carcinoma An Bras Dermatol, 92 (2017)

19 S.V. Mohan, A.L. ChangAdvanced basal cell carcinoma: epidemiology and therapeutic innovations Curr Dermatol Rep, 3 (1) (2014), pp. 40-45, 10.1007/s13671-014-0069-y

20 K.D. Robarge, S.A. Brunton, G.M. Castanedo, et al.GDC-0449-a potent inhibitor of the hedgehog pathway Bioorg Med Chem Lett, 19 (19) (2009), pp. 5576-5581, 10.1016/j.bmcl.2009.08.049

21 P.M. LoRusso, C.M. Rudin, J.C. Reddy, et al.Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res, 17 (8) (2011), pp. 2502-2511, 10.1158/1078-0432.Ccr-10-2745

22 M. Aszterbaum, A. Rothman, R.L. Johnson, et al.Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome J Invest Dermatol, 110 (6) (1998), pp. 885-888, 10.1046/j.1523-1747.1998.00222.x

23 E.M. AgencyErivedge. Summary of Product Characteristics Available from (2023) https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf

24 N. Basset-Séguin, A. Hauschild, R. Kunstfeld, et al.Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial Eur J Cancer, 86 (2017), pp. 334-348, 10.1016/j.ejca.2017.08.022

25 A. Sekulic, M.R. Migden, N. Basset-Seguin, et al.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study BMC Cancer, 17 (1) (2017), p. 332, 10.1186/s12885-017-3286-5

26 N. Bertrand, P. Guerreschi, N. Basset-Seguin, et al.Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma Clin Med, 35 (2021), 10.1016/j.eclinm.2021.100844

27 A. Kahana, S.P. Unsworth, C.A. Andrews, et al.Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial Oncol, 26 (7) (2021), pp. e1240-e1249, 10.1002/onco.13820

28 R. Dummer, A. Guminksi, R. Gutzmer, et al.Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study Br J Dermatol, 182 (6) (2020), pp. 1369-1378, 10.1111/bjd.18552

29 K.S. Nehal, C.K. BichakjianUpdate on keratinocyte carcinomas N Engl J Med, 379 (4) (2018), pp. 363-374, 10.1056/NEJMra1708701

30 J.R. Kallini, N. Hamed, A. KhachemouneSquamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends Int J Dermatol, 54 (2) (2015), pp. 130-140, 10.1111/ijd.12553

31 R.B. Diasio, B.E. HarrisClinical pharmacology of 5-fluorouracil Clin Pharmacokinet, 16 (4) (1989), pp. 215-237, 10.2165/00003088-198916040-00002

32 J.E. HouglumInterferon: mechanisms of action and clinical value Clin Pharm, 2 (1) (1983), pp. 20-28

33 J. Verweij, H.M. PinedoMitomycin C: mechanism of action, usefulness and limitations Anti Cancer Drugs, 1 (1) (1990), pp. 5-13

34 N.W. Gibson, R.M. Phillips, D. Ross, et al. Cancer Chemother Biol Response Modif, 15 (1994), pp. 51-57

35 C.L. Shields, H. Demirci, E. Karatza, et al.Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors Ophthalmology, 111 (9) (2004), pp. 1747-1754, 10.1016/j.ophtha.2004.02.013

36 G. Al Bayyat, D. Arreaza-Kaufman, N. Venkateswaran, et al.Update on pharmacotherapy for ocular surface squamous neoplasia Eye Vis (Lond)., 6 (2019), p. 24, 10.1186/s40662-019-0150-5

37 C.V. Miller, A. Wolf, A. Klingenstein, et al.Clinical outcome of advanced squamous cell carcinoma of the conjunctiva Eye (Lond)., 28 (8) (2014), pp. 962-967, 10.1038/eye.2014.79

38 D.B. Rootman, H.D. McGowan, Y.H. Yücel, et al.Intraocular extension of conjunctival invasive squamous cell carcinoma after pterygium surgery and cataract extraction Eye Contact Lens, 38 (2) (2012), pp. 133-136, 10.1097/ICL.0b013e318235c4d3

39 S. Ch'ng, I. Low, D. Ng, et al.Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma Hum Pathol, 39 (3) (2008), pp. 344-349, 10.1016/j.humpath.2007.07.004

40 T.R. Shepler, V.G. Prieto, R. Diba, et al.Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma Ophthalmic Plast Reconstr Surg, 22 (2) (2006), pp. 113-115, 10.1097/01.iop.0000202609.92772.c3

41 J.B. Vermorken, R. Mesia, F. Rivera, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med, 359 (11) (2008), pp. 1116-1127, 10.1056/NEJMoa0802656

42 R. Hitt, A. Irigoyen, H. Cortes-Funes, et al.Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck Ann Oncol, 23 (4) (2012), pp. 1016-1022, 10.1093/annonc/mdr367

43 J.A. Bonner, P.M. Harari, J. Giralt, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med, 354 (6) (2006), pp. 567-578, 10.1056/NEJMoa053422

44 FdaFDA approves first treatment for advanced form of the second most common skin cancer Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer (2018)

45 M.R. Migden, D. Rischin, C.D. Schmults, et al.PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma N Engl J Med, 379 (4) (2018), pp. 341-351, 10.1056/NEJMoa1805131

46 B.E. Cook, G.B. BartleyEpidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted county, Minnesota Ophthalmology, 106 (4) (1999), pp. 746-750, 10.1016/S0161-6420(99)90161-6

47 N. Mancera, K.S.M. Smalley, C.E. MargoMelanoma of the eyelid and periocular skin: histopathologic classification and molecular pathology Surv Ophthalmol, 64 (3) (2019), pp. 272-288, 10.1016/j.survophthal.2018.12.002

48 V. Pinto, G. Zannetti, R. Villani, et al.Long term cosmetic and functional results of one stage reconstruction for lower eyelid malignant melanoma: a single centre experience of eleven patients J Maxillofac Oral Surg, 17 (4) (2018), pp. 625-629, 10.1007/s12663-016-0932-4

49 V. Saranga-Perry, C. Ambe, J.S. Zager, et al.Recent developments in the medical and surgical treatment of melanoma. Ca - Cancer J Clin, 64 (3) (2014), pp. 171-185, 10.3322/caac.21224

50 J.E. Ma, J.D. BrewerMerkel cell carcinoma in immunosuppressed patients Cancers (Basel), 6 (3) (2014), pp. 1328-1350, 10.3390/cancers6031328

51 P.K. Bommareddy, H.L. KaufmanAvelumab and other recent advances in Merkel cell carcinoma Future Oncol, 13 (30) (2017), pp. 2771-2783, 10.2217/fon-2017-0305

52 R. Hoerster, M. Schlaak, K.R. Koch, et al.[Merkel cell carcinoma of the eyelid. An often unrecognized tumor entity : clinical aspects and treatment strategies] Ophthalmologe, 114 (2) (2017), pp. 134-139, 10.1007/s00347-016-0355-0

53 Y. Han, D. Liu, L. LiPD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res, 10 (3) (2020), pp. 727-742

54 P. Donizy, C.L. Wu, J. Kopczynski, et al.Prognostic role of tumoral PD-L1 and Ido1 expression, and intratumoral CD8+ and FoxP3+ lymphocyte infiltrates in 132 primary cutaneous merkel cell carcinomas Int J Mol Sci, 22 (11) (2021), 10.3390/ijms22115489

55 C. Ricci, L. Morandi, A. Righi, et al.PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters Mod Pathol, 32 (9) (2019), pp. 1359-1372, 10.1038/s41379-019-0261-5

56 S.P. D'Angelo, S. Bhatia, A.S. Brohl, et al.Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial J Immunother Cancer, 8 (1) (2020), 10.1136/jitc-2020-000674

57 S.P. D'Angelo, C. Lebbé, L. Mortier, et al.First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study J Immunother Cancer, 9 (7) (2021), 10.1136/jitc-2021-002646

58 S. Bhatia, P. Nghiem, S.P. Veeranki, et al.Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study J Immunother Cancer, 10 (8) (2022), 10.1136/jitc-2022-004904

59 J.W. Walker, C. Lebbé, G. Grignani, et al.Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program J Immunother Cancer, 8 (1) (2020), 10.1136/jitc-2019-000313

60 I. Averbuch, R. Stoff, M. Miodovnik, et al.Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel Cancer Med, 12 (11) (2023), pp. 12065-12070, 10.1002/cam4.5890

61 FDA Approves Pembrolizumab for Merkel Cell Carcinoma (2018)

62 P.T. Nghiem, S. Bhatia, E.J. Lipson, et al.PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma N Engl J Med, 374 (26) (2016), pp. 2542-2552, 10.1056/NEJMoa1603702

63 P. Nghiem, S. Bhatia, E.J. Lipson, et al.Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy J Clin Oncol, 37 (9) (2019), pp. 693-702, 10.1200/jco.18.01896

64 G.K. Vora, H. Demirci, B. Marr, et al.Advances in the management of conjunctival melanoma Surv Ophthalmol, 62 (1) (2017), pp. 26-42, 10.1016/j.survophthal.2016.06.001

65 S. Kaštelan, A. Gverović Antunica, L. Beketić Orešković, et al.Conjunctival melanoma - epidemiological trends and features Pathol Oncol Res, 24 (4) (2018), pp. 787-796, 10.1007/s12253-018-0419-3

66 C.L. Shields, J.S. Markowitz, I. Belinsky, et al.Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases Ophthalmology, 118 (2) (2011), pp. 389-395, 10.1016/j.ophtha.2010.06.021 e1-2

67 R.R. Pacheco, A. Yaghy, L.A. Dalvin, et al.Conjunctival melanoma: outcomes based on tumour origin in 629 patients at a single ocular oncology centre Eye (Lond)., 36 (3) (2022), pp. 603-611, 10.1038/s41433-021-01508-y

68 J.R. Wong, A.A. Nanji, A. Galor, et al.Management of conjunctival malignant melanoma: a review and update Expet Rev Ophthalmol, 9 (3) (2014), pp. 185-204, 10.1586/17469899.2014.921119

69 J.P. Glossmann, N. Skoetz, B. Starbatty, et al.[Conjunctival melanoma : standard operating procedures in diagnosis, treatment and follow-up care] Ophthalmologe, 115 (6) (2018), pp. 489-498, 10.1007/s00347-018-0664-6

70 A.C. Larsen, C. Dahl, C.M. Dahmcke, et al.BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions Acta Ophthalmol, 94 (5) (2016), pp. 463-470, 10.1111/aos.13007

71 S. Gardrat, A. Houy, K. Brooks, et al.Definition of biologically distinct groups of conjunctival melanomas according to etiological factors and implications for precision medicine Cancers (Basel), 13 (15) (2021), 10.3390/cancers13153836

72 S.E. Lally, T. Milman, M. Orloff, et al.Mutational landscape and outcomes of conjunctival melanoma in 101 patients Ophthalmology, 129 (6) (2022), pp. 679-693, 10.1016/j.ophtha.2022.01.016

73 N.M. van Poppelen, J.A. van Ipenburg, Q. van den Bosch, et al.Molecular genetics of conjunctival melanoma and prognostic value of TERT promoter mutation analysis Int J Mol Sci, 22 (11) (2021), 10.3390/ijms22115784

74 H.E. Spendlove, B.E. Damato, J. Humphreys, et al.BRAF mutations are detectable in conjunctival but not uveal melanomas Melanoma Res, 14 (6) (2004), pp. 449-452, 10.1097/00008390-200412000-00003

75 A.Y. Goh, C.A. Ramlogan-Steel, K.S. Jenkins, et al.Presence and prevalence of UV related genetic mutations in uveal melanoma: similarities with cutaneous melanoma Neoplasma, 67 (5) (2020), pp. 958-971, 10.4149/neo_2020_190815N768

76 B. Royer-Bertrand, M. Torsello, D. Rimoldi, et al.Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing Am J Hum Genet, 99 (5) (2016), pp. 1190-1198, 10.1016/j.ajhg.2016.09.008

77 J. Cao, R.C. Heijkants, A.G. Jochemsen, et al.Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy Oncotarget, 8 (35) (2017), pp. 58021-58036, 10.18632/oncotarget.10770

78 J.M. Mor, L.M. HeindlSystemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma Ocul Oncol Pathol, 3 (2) (2017), pp. 133-141, 10.1159/000452473

79 D.R. Green, T. Ferguson, L. Zitvogel, et al.Immunogenic and tolerogenic cell death Nat Rev Immunol, 9 (5) (2009), pp. 353-363, 10.1038/nri2545

80 P. Sharma, J.P. AllisonImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell, 161 (2) (2015), pp. 205-214, 10.1016/j.cell.2015.03.030

81 C. Boutros, A. Tarhini, E. Routier, et al.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Nat Rev Clin Oncol, 13 (8) (2016), pp. 473-486, 10.1038/nrclinonc.2016.58

82 J.M. Grimes, N.V. Shah, F.H. Samie, et al.Conjunctival melanoma: current treatments and future options Am J Clin Dermatol, 21 (3) (2020), pp. 371-381, 10.1007/s40257-019-00500-3

83 B. Cybulska-Stopa, P. Rogala, A.M. Czarnecka, et al.Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - real world evidence Adv Med Sci, 65 (2) (2020), pp. 316-323, 10.1016/j.advms.2020.05.005

84 G.A. Lee, L.W. HirstOcular surface squamous neoplasia Surv Ophthalmol, 39 (6) (1995), pp. 429-450, 10.1016/s0039-6257(05)80054-2

85 C.A. Kiire, S. Srinivasan, C.L. KarpOcular surface squamous neoplasia Int Ophthalmol Clin, 50 (3) (2010), pp. 35-46, 10.1097/IIO.0b013e3181e246e5

86 R. Hollhumer, S. Williams, P. Michelow Ocul Surf Squamous Neoplasia: Popul Demogr, Pathog Risk Factors, 79 (1) (2020), 10.4102/aveh.v79i1.553 2020

87 R. Hӧllhumer, S. Williams, P. MichelowOcular surface squamous neoplasia: management and outcomes Eye (Lond)., 35 (6) (2021), pp. 1562-1573, 10.1038/s41433-021-01422-3

88 M.G. Joag, A. Sise, J.C. Murillo, et al.Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia Ophthalmology, 123 (7) (2016), pp. 1442-1448, 10.1016/j.ophtha.2016.02.034

89 N. Venkateswaran, C. Mercado, A. Galor, et al.Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia Am J Ophthalmol, 199 (2019), pp. 216-222, 10.1016/j.ajo.2018.11.007

90 S.U. Shah, S. Kaliki, H.J. Kim, et al.Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification Arch Ophthalmol, 130 (2) (2012), pp. 159-164, 10.1001/archophthalmol.2011.385

91 R. Kusumesh, A. Ambastha, B. Sinha, et al.Topical interferon α-2b as a single therapy for primary ocular surface squamous neoplasia The Asia-Pacific Journal of Ophthalmology, 4 (5) (2015), pp. 279-282

92 C.L. Shields, A.B. Constantinescu, S.A. Paulose, et al.Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: comparative analysis of outcomes based on original tumor configuration Indian J Ophthalmol, 69 (3) (2021), pp. 563-567, 10.4103/ijo.IJO_1665_20

93 J.J. Khong, J. MueckeComplications of mitomycin C therapy in 100 eyes with ocular surface neoplasia Br J Ophthalmol, 90 (7) (2006), pp. 819-822, 10.1136/bjo.2005.086850

94 P.L. Ballalai, C.M. Erwenne, M.C. Martins, et al.Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia Ophthalmic Plast Reconstr Surg, 25 (4) (2009), pp. 296-299, 10.1097/IOP.0b013e3181ac4c39

95 H.C. Russell, V. Chadha, D. Lockington, et al.Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications Br J Ophthalmol, 94 (10) (2010), pp. 1316-1321, 10.1136/bjo.2009.176099

96 L.W. HirstRandomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution Ophthalmology, 114 (5) (2007), pp. 976-982, 10.1016/j.ophtha.2006.09.026

97 Y. Sun, R. HuaLong-term efficacy and safety of subconjunctival/perilesional 5-fluorouracil injections for ocular surface squamous neoplasia Drug Des Dev Ther, 14 (2020), pp. 5659-5665, 10.2147/dddt.S285752

98 C.L. Karp, A. Galor, S. Chhabra, et al.Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review Ophthalmology, 117 (12) (2010), pp. 2241-2246, 10.1016/j.ophtha.2010.03.052

99 E. Adler, J.R. Turner, D.U. StoneOcular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012 Cornea, 32 (12) (2013), pp. 1558-1561, 10.1097/ICO.0b013e3182a6ea6c

100 H.J. Kim, C.L. Shields, S.U. Shah, et al.Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction Ophthalmology, 119 (5) (2012), pp. 938-944, 10.1016/j.ophtha.2011.11.035

101 P. Prabhasawat, P. Tarinvorakup, N. Tesavibul, et al.Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma Cornea, 24 (4) (2005), pp. 443-448, 10.1097/01.ico.0000148314.86557.6a

102 J. Frucht-Pery, J. Sugar, J. Baum, et al.Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience Ophthalmology, 104 (12) (1997), pp. 2085-2093, 10.1016/s0161-6420(97)30055-4

103 P. Nagarajan, C. El-Hadad, S.K. Gruschkus, et al.PD-L1/PD1 expression, composition of tumor-associated immune infiltrate, and HPV status in conjunctival squamous cell carcinoma Invest Ophthalmol Vis Sci, 60 (6) (2019), pp. 2388-2398, 10.1167/iovs.19-26894

104 N. Wolkow, F.A. Jakobiec, A.H. Afrogheh, et al.Programmed cell death 1 ligand 1 and programmed cell death 1 ligand 2 are expressed in conjunctival invasive squamous cell carcinoma: therapeutic implications Am J Ophthalmol, 200 (2019), pp. 226-241, 10.1016/j.ajo.2018.12.020

105 G.K. In, P. Vaidya, A. Filkins, et al.PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California J Cancer Res Clin Oncol, 147 (6) (2021), pp. 1803-1811, 10.1007/s00432-020-03458-6

106 H. Demirci, V.M. Elner, F.Y. Demirci, et al.Immunotherapy for conjunctival squamous cell carcinoma with orbital extension Ophthalmology, 128 (5) (2021), pp. 801-804, 10.1016/j.ophtha.2020.09.027

107 M. Hoffmann, J. Schardt, C. Ionescu, et al.Long lasting response to anti-PD-1 therapy of recurrent conjunctival squamous cell carcinoma - a case report and systematic review of the literature Curr Probl Cancer: Case Reports, 4 (2021), Article 100088, 10.1016/j.cpccr.2021.100088

108 J.M. Kim, S. Weiss, J.H. Sinard, et al.Dabrafenib and trametinib for BRAF-mutated conjunctival melanoma Ocul Oncol Pathol, 6 (1) (2020), pp. 35-38, 10.1159/000497473

109 J.L. Weber, K.S. Smalley, V.K. Sondak, et al.Conjunctival melanomas harbor BRAF and NRAS mutations Clin Cancer Res, 19 (22) (2013), pp. 6329-6330

110 K.G. Griewank, H. Westekemper, R. Murali, et al.Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas Clin Cancer Res, 19 (12) (2013), pp. 3143-3152

111 A. Maleka, G. Åström, P. Byström, et al.A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib BMC Cancer, 16 (2016), pp. 1-5

112 S. Pinto Torres, T. André, E. Gouveia, et al.Systemic treatment of metastatic conjunctival melanoma Case Reports in Oncological Medicine (2017), p. 2017

113 L.R.D. Glass, D.P. Lawrence, F.A. Jakobiec, et al.Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors Ophthalmic Plast Reconstr Surg, 33 (5) (2017), pp. e114-e116

114 E. Rossi, B.A. Maiorano, M.M. Pagliara, et al.Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma Front Oncol, 9 (2019), p. 232

115 J.H. Francis, C. Barker, L.R. Koenig, et al.Conjunctival melanoma and cell-free DNA regression with ipilimumab/nivolumab and stereotactic radiosurgery Ophthalmic Plast Reconstr Surg (2023), 10.1097/IOP.0000000000002490

116 K. Fan, J.J. Waninger, S. Yentz, et al.Neoadjuvant immune checkpoint inhibition in metastatic conjunctival melanoma Ophthalmic Plast Reconstr Surg, 39 (5) (2023), pp. e152-e155, 10.1097/iop.0000000000002407

117 N.J. Brouwer, R.M. Verdijk, S. Heegaard, et al.Conjunctival melanoma: new insights in tumour genetics and immunology, leading to new therapeutic options Prog Retin Eye Res, 86 (2022), p. 100971, 10.1016/j.preteyeres.2021.100971